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Aryl hydrocarbon receptorIDO1, which encodes the immunosuppressive and tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase-
1 (IDO1), is a target for interferon-γ (IFN-γ). IDO1-mediated tryptophan catabolism in dendritic cells and macro-
phages arrests T cell proliferation, thereby providing a molecular basis for the immunosuppressive function of
IDO1. Whether the entry of tryptophan into IDO1-expressing cells is also regulated by IFN-γ is not known.
Here we used a human colonic epithelial cell line (CCD841) and a mouse dendritic cell line (DC2.4) to test the
hypothesis that IFN-γ, which induces IDO1, also induces a tryptophan transporter to promote substrate availability
to IDO1. Upon treatment with IFN-γ, there was a marked increase in IDO1 mRNA and a concomitant increase in
tryptophan uptake in both cell lines. The induced uptake system was selective for tryptophan and saturable
with a Michaelis constant of 36 ± 3 μM in CCD841 cells and 0.5 ± 0.1 μM in DC2.4 cells. The induction by IFN-γ
and the tryptophan-selectivity of the induced transport system were demonstrable even in the presence of
physiologic concentrations of all other amino acids. Since kynurenine, the catabolic end product of IDO1, is a
signaling molecule as an agonist for the aryl hydrocarbon receptor (AhR), we examined if AhR signaling induces
the tryptophan-selective transporter. Treatment of the cells with kynurenine and other AhR agonists increased
tryptophan uptake. The present studies demonstrate that IFN-γ coordinately induces IDO1 and a tryptophan-
selective transporter to maximize tryptophan depletion in IDO1-expressing cells and that the process involves
a positive feedback mechanism via kynurenine-AhR signaling.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Tryptophan is an essential amino acid and the least abundant of all
dietary amino acids, required by all forms of life for protein synthesis. It
is also the precursor for the synthesis of biologically important signaling
molecules serotonin andmelatonin. Recent studies have shown that this
amino acid plays an obligatory role in the immune system through the
enzyme indoleamine 2,3-dioxygenase (IDO) [1,2]. IDO is a tryptophan-
catabolizing enzyme and produces kynurenine as one of the catabolicdioxygenase; TDO, tryptophan
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utia).end products. There are three enzymes that participate in tryptophan
catabolism: IDO1, IDO2, and biologically related tryptophan dioxygenase
(TDO) [3]. Of these, IDO1 has been investigated the most for its role in
immune function. It is considered as an immunosuppressive molecule
because its expression in certain immune cells such as the dendritic
cells and macrophages is induced by interferon-γ (IFN-γ) and the
resultant increased catabolism of tryptophan in IDO1-expressing cells
arrests T cell proliferation and causes T cell anergy [1,2]. The precise
mechanisms by which tryptophan degradation in dendritic cells/
macrophages is linked to T cell function are poorly understood.
Potential mechanisms include depletion of tryptophan in the T cell
microenvironment, thus causing the deﬁciency of an essential amino
acid in T cells and consequent cessation of protein synthesis and
initiation of signaling pathways involving the stress kinase GCN2 and
suppression of the nutrient-sensing receptor mTOR [4,5]. Since
kynurenine, generated by IDO1-mediated degradation of tryptophan,
is an important signaling molecule by serving as an agonist for the
aryl hydrocarbon receptor AhR, the signaling cascade initiated in T
cells by this metabolite may also contribute to the mechanism [6–8].
Yet another potential mechanism is the involvement of the G-protein-
coupled receptor GPR35, which is activated by kynurenic acid that is
generated from kynurenine [9]. Irrespective of the actual mechanism
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phan catabolism in dendritic cells and macrophages in immune
suppression remains an established phenomenon.
IDO1 is a heme-containing enzyme that is expressed in various
organs, particularly the placenta, intestinal tract, and immune cells.
IDO1-mediated immunosuppression at the maternal–fetal interface
of the placenta might play an important role in the maternal tolerance
of the allogeneic fetus [10]. The intestinal tract, speciﬁcally the
colon, is in contact with a wide variety of microorganisms as part
of the gut microbiome, and the IDO1-mediated immunosuppression
may be essential to maintain the “truce” between these micro-
organisms and the host and promote a symbiotic relationship [11].
Many immunogenic and tolerogenic signals regulate IDO1 induction;
most importantly, it is induced in response to the inﬂammatory
cytokine IFN-γ [12].
The role of IDO1 in colon cancer is not clearly understood since it
has potential to act as a double-edged sword [13–15]. Basal expression
is seen in immune cells present in the lamina propria of the colon
and also in colonocytes to maintain the gut homeostasis but the
expression is increased under conditions such as inﬂammatory bowel
disease and inﬂammatory colitis that facilitate colon cancer. In a
mild inﬂammatory state, IDO1 acts as a natural brake in response
to the inﬂammatory situation but as the inﬂammation increases
in severity, IDO1 expression persists which can ultimately lead to
tumorigenesis. The fundamental role of IDO1 being in immune suppres-
sion and reduced inﬂammation, it is perplexing that its expression can
also promote colon cancer. It is important however to recognize
that IDO1 impacts on multiple signaling pathways, which include
not only tryptophan depletion but also kynurenine-dependent AhR
signaling and kynurenic acid-dependent GPR35 signaling, and that
these pathways may have different effects on inﬂammation, immune
tolerance, tumor progression, and tumor-induced immune escape. The
involvement of a plethora of signaling events with different biological
effects as a consequence of IDO1 activity potentially underlies the seem-
ingly contradictory reports in the literature on the biological outcome
of IDO1 induction under various physiological and pathological
conditions.
Tryptophan is the substrate for IDO1; it is the degradation of this
amino acid inside the cells via IDO1 that initiates the biological effects
irrespective of whether such effects depend on tryptophan depletion
or on tryptophan catabolic end products. IDO1, being an intracellular
enzyme, cannot elicit its effects unless this amino acid enters the cells
from the extracellular milieu. Tryptophan however does not diffuse
into cells; the entry is certainly mediated by speciﬁc transport systems.
Therefore, the biological function of IDO1 must depend on the expres-
sion and activity of the transport system that is responsible for trypto-
phan entry into IDO1-expressing cells. In spite of this obligatory
relationship between IDO1 and tryptophan transport, surprisingly the
primary focus in IDO1 research has been on IDO1 or its catabolic end
productswith no or little attention on the tryptophan entrymechanism.
To date, there have been only two reports in the literature studying
tryptophan transport in the context of IDO1 [16,17]. Both studies have
identiﬁed a novel transport system in IDO1-expressing cells that
shows preferential afﬁnity for tryptophan. However, neither of these
studies addressed the question as to whether there is a coordinated
induction of IDO1 and the tryptophan transport system. The purpose
of the present study was therefore to determine the inﬂuence of IFN-
γ, the cytokine most studied for its ability to induce IDO1, on the trans-
port system responsible for tryptophan delivery into IDO1-expressing
cells. Since the enzyme is expressed in colonic epithelial cells as well
as immune cells, we conducted the present study with a human colonic
epithelial cell line (CCD841) and a mouse dendritic cell line (DC2.4).
The results of this study demonstrate that IFN-γ induces IDO1 in
both of these cell lines and at the same time coordinately induces a
tryptophan-selective transport system to optimize the biological effects
of the induced enzyme.2. Materials and methods
2.1. Materials
[3H]-tryptophan (speciﬁc radioactivity, 20 Ci/mmol) was purchased
from American Radiolabeled Chemicals (St. Louis, MO, USA). All amino
acids including tryptophan, L-1-methyl tryptophan (L-1-MT), D-1-methyl
tryptophan (D-1-MT), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),
benzo[a]pyrene (B[a]P), 3-methylcholanthrene (3MC), and indole-3-
carbinol (I3C) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Human and mouse interferon-γ (IFN-γ) were purchased from
Bio AbChem (Ladson, SC, USA). Fetal bovine serum was from Atlanta
Biologicals (Atlanta, GA, USA) and plasticware for cell culture were
obtained from Corning (New York, NY, USA). TRIzol and the power
SYBR green were procured from Invitrogen Life Technologies (Grand
Island, NY, USA).
2.2. Cell culture
The human colonic epithelial cell line (CCD841) and the mouse
dendritic cell line (DC2.4) were procured from the American Type
Culture Collection (Manassas, VA, USA). They were both cultured in
RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum,
100 units/mL penicillin and 2 mg/mL streptomycin (Sigma-Aldrich).
The cells were incubated at 37 °C in a 5% CO2 environment and
subcultured every 48–96 h at a 1:5 ratio. The cell lineswere propagated,
expanded, and frozen immediately after arrival. The cells revived from
the frozen stock were used within 10–20 passages, not exceeding a
period of 2–3 months. The media were purchased from MediaTech
(Atlanta, GA, USA).
2.3. Uptake measurements
Uptake experiments were carried out as described previously [18].
Brieﬂy, CCD841 cells were seeded in 24-well culture plates at an initial
density of 8 × 104 cells/assay. The DC2.4 cell line was cultured in
suspension; the approximate number of cells required for the uptake
experiment was calculated and allowed to grow in T75 tissue culture
ﬂask. The following day, CCD841 and DC2.4 cells were treated with
10 ng/mL of human IFN-γ and 20 ng/mL mouse IFN-γ, respectively,
for 24 h. Following treatment, DC2.4 cells were counted and used at
2 × 106 cells/assay whereas CCD841 were seeded in 24-well plate and
used as such. Cells cultured under identical conditions but in the
absence of IFN-γ served as controls in each experiment. To initiate the
uptake, the culture medium was ﬁrst aspirated out and the cells were
washed twice with N-methyl-D-glucamine (NMDG)-chloride (uptake
buffer). This was followed by the addition of 250 μL uptake buffer
containing [3H]-tryptophan (0.5 μCi/assay; 0.1 μM) and 5 mM leucine
(to inhibit the activity of the polyspeciﬁc amino acid transporter
LAT1) and incubated for 2 min at 37 °C. At the end of the uptake reac-
tion, the substrate was aspirated (ﬁltered in case of DC2.4) and the
cells were washed with ice-cold uptake buffer twice, and then lysed
with 500 μL of lysis buffer (1% sodium dodecyl sulfate/0.2 N NaOH).
The cell lysates (CCD841) and membrane ﬁlters (DC2.4) were collected
and added into a scintillation vial containing the scintillation cocktail.
Using the liquid scintillation counter, the radioactivity in the resultant
cell lysate was measured. All assays were performed in triplicate. The
uptake rate was normalized to cell number and expressed as pmoles/
106 cells/2 min. The uptake buffer consisted of 25 mM Hepes/Tris
(pH 7.5), containing 140 mM NMDG chloride, 5.4 mM KCl, 1.8 mM
CaCl2, 0.8 mM MgSO4, and 5 mM glucose. Under these experimental
conditions, the value for tryptophan uptake in control CCD841 cells
(i.e., without treatment with IFN-γ) was 0.10 ± 0.01 pmoles/
106 cells/2 min; the corresponding value for control DC2.4 cells was
0.32 ± 0.04 pmoles/106 cells/2 min. These values were taken as 100%
in respective cells to compare the induction of tryptophan uptake in
Table 1
Human primer sequences used for real-time quantitative RT-PCR.
Protein name Gene name Orientation Sequence
ASCT1 SLC1A4 Forward GGC CTT GGC GTT CAT CAT CA
ASCT1 SLC1A4 Reverse GTT GCA TAC GTA CGG AAA GCT G
ASCT2, AAAT SLC1A5 Forward GCC ATC AAC GCC TCC GTG GGA
ASCT2, AAAT SLC1A5 Reverse ACG GGC ACC TTC ACC CTG GTT C
rBAT SLC3A1 Forward TCC ACC CAA CAA CTG GTT AAG
rBAT SLC3A1 Reverse ACC CTT TGT GAG CCA GAA CC
4F2hc SLC3A2 Forward CTC GTG GTT CTC CAC TCA GG
4F2hc SLC3A2 Reverse CCG CAA TCA AGA GCC TGT CT
ATB0,+ SLC6A14 Forward GGG TCT CGA TTC TCA GTT TGC T
ATB0,+ SLC6A14 Reverse CCC AGT AAA TTC CAG CCT GAG T
B0AT1 SLC6A19 Forward TCC ATC CAC CCG GCC CTG AAG
B0AT1 SLC6A19 Reverse ACT CGT CCA CAT ACC CTG TCT GGT
CAT-1 SLC7A1 Forward CTC GGG TGC CGT TGC TGC TGT
CAT-1 SLC7A1 Reverse CAG GTT AGG CTG CTC TGG CTG G
CAT-2 SLC7A2 Forward TGT CAA CAA GTC TTC TGG GCT
CAT-2 SLC7A2 Reverse CAA GCG CCT TCA GGT CAA AC
LAT1 SLC7A5 Forward CCG TGC CGT CCC TCG TGT TC
LAT1 SLC7A5 Reverse GGT TCA CCT TGA TGG GCC GCT
LAT2 SLC7A8 Forward TCG GCT CCT GGC TGC CAT CT
LAT2 SLC7A8 Reverse CCA GCC AGA AGT ACT CTC CTT TGC
b0,+ SLC7A9 Forward CCT GGC CCA AGG AAA CAC AA
b0,+ SLC7A9 Reverse ATG GCC AAA GGC AGG TTT CT
xCT SLC7A11 Forward TGG ACG GTG TGT GGG GTC CT
xCT SLC7A11 Reverse CAG CAG TAG CTG CAG GGC GTA
MCT5 SLC16A4 Forward GGT TGG ATT GGA TCC ATC ATG T
MCT5 SLC16A4 Reverse CAG AAC CCA AAC CGG GTA GA
MCT6 SLC16A5 Forward GCC AGC TCT ACT TCA CAG CA
MCT6 SLC16A5 Reverse GCG GAC AAA GTA GAA GCC CA
MCT7 SLC16A6 Forward TCA TAT GTA CGT CGC CAT CGG
MCT7 SLC16A6 Reverse TCA GAG CCA TGA TTG CTG GT
MCT9 SLC16A9 Forward GAT CCC TGG CAA GTG GAG TT
MCT9 SLC16A9 Reverse ACC ACA TCC AAG ACC TAC AAC A
TAT1, MCT10 SLC16A10 Forward TCG GCT CCA AAG ACG ATG AC
TAT1, MCT10 SLC16A10 Reverse CAG AGG CTC GAT GGA ACT TAC
MCT11 SLC16A11 Forward CCG CTG GTT TTC GGT GTA CT
MCT11 SLC16A11 Reverse TTA GGA AGC CTG ACA GGG GA
MCT12 SLC16A12 Forward ATT GTG GCT GGC TGT TTC CT
MCT12 SLC16A12 Reverse CTC CCA AGT GGA GCA CAG AG
MCT13 SLC16A13 Forward TTT GGG AGC CCG GTA GGC
MCT13 SLC16A13 Reverse GGT CGG AGC GAA GGT CAA A
MCT14 SLC16A14 Forward AAG AAT TCC ACC AGA GCC GC
MCT14 SLC16A14 Reverse CGG CAC CCA CAG GTG TTA AT
PAT4 SLC36A4 Forward ATG TTG TCA GGA ACA TGC CAG
PAT4 SLC36A4 Reverse TTC AAC GCT TGA GGG AAA CG
SNAT1, ATA1 SLC38A1 Forward GCC ATT ATG GGC AGT GGG AT
SNAT1, ATA1 SLC38A1 Reverse ACA CCA TGC AGC CTG TTT CT
SNAT2, ATA2 SLC38A2 Forward TGG GCA GTG GAA TCC TTG GGC
SNAT2, ATA2 SLC38A2 Reverse AAA GAC CCT CCT TCA TTG GCA GTC T
SNAT3, SN1 SLC38A3 Forward ATC GGA GCC ATG TCC AGC TA
SNAT3, SN1 SLC38A3 Reverse AGG GGC AGA ATG ATG GTG AC
EEG1 SLC43A3 Forward ACT ACA GCT ATG GCC TGT GC
EEG1 SLC43A3 Reverse CAG AAG GAG CGG AGT TCC TG
CD147 EMMPRIN Forward CAG TCG TGC TAG TCC TGG AA
CD147 EMMPRIN Reverse TCG TCG GAG TCC ACC TTG A
ACE2 Forward GTG GGA GAT GAA GCG AGA GAT
ACE2 Reverse AGC TGC TTG ACA AAG TGC TTC
IDO1 Forward CAG GCA GAT GTT TAG CAA TGA
IDO1 Reverse GAT GAA GAA GTG GGC TTT GC
IDO2 Forward GGC TCT TGG GAA ACT CCT TC
IDO2 Reverse TCA GGA CAT CAC CAA AAC CTT
TDO Forward TGG GAA CTA CCT GCA TTT GGA
TDO Reverse CCA ACT CCC AGA GGA TTT GCT
HPRT Forward GCG TCG TGA TTA GCG ATG ATG AAC
HPRT Reverse CCT CCC ATC TCC TTC ATG ACA TCT
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maximal velocity Vmax) were determined using the computer program
Sigma Plot, version 10.0 (SPSS, Inc., Chicago, IL, USA). These determina-
tions were made by non-linear regression analysis and the values
conﬁrmed by linear regression analysis according to the Eadie–Hofstee
transformation of the Michaelis–Menten equation. Statistical analysis
was done using the paired Student's t test. A P b 0.05 was taken as
statistically signiﬁcant. Experiments were repeated at least three times
and measurements were made in triplicate for each experimental
condition. Data are presented as means ± S.E.M.
2.4. Real-time PCR analysis
Real-time PCR was carried out in an Applied Biosystems Step One
Plus instrument using the power SYBR green PCRmaster mix according
to themanufacturer's instructions. Total RNAwas isolated fromCCD841
cells and DC2.4 cells treatedwith andwithout human andmouse IFN-γ,
using Trizol. The RNAwas reverse transcribed using high capacity cDNA
reverse transcription kit (Applied Biosystems, Carlsbad, CA, USA). The
primers used for the real-time PCR analysis are listed in Table 1
(human) andTable 2 (mouse). In each case, the experimentwas repeated
with biological triplicates.
2.5. Microarray analysis
Total RNA was extracted from CCD841 cells treated with and
without human IFN-γ (10 ng/mL for 24 h) using Trizol and the quality
of the extracted RNA was analyzed using 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). The labeled single-stranded cDNA
was prepared using the total RNA (250 ng) according to the Ambion
WT Expression Kit (Life Technologies, Carlsbad, CA, USA) and GeneChip
WT Terminal Labeling kit (Affymetrix, Santa Clara, CA, USA), and then
hybridized to an AffymetrixGeneGhip Human Gene 1.0 ST Array. The
washing, staining and scanning of the arrays were conducted using a
Fluidics 450 station and GeneChip Scanner 3000 (Affymetrix). The
analysiswas donewith biological triplicates for control and treated cells.
3. Results
3.1. IFN-γ induces IDO in CCD841 and DC2.4 cells
In normal colon, IDO1 is expressed primarily in immune cells
present in the lamina propria and, to a lesser extent, in epithelial cells;
but the expression in both cell types increase under inﬂammatory con-
ditions [19,20]. This suggests that pro-inﬂammatory cytokines might
induce the expression of IDO1 not only in immune cells but also in
epithelial cells in colon. Several studies have demonstrated the ability
of IFN-γ to induce IDO1 in immune cells but this phenomenon has not
yet been demonstrated directly in colonic epithelial cells. Therefore,
we ﬁrst wanted to investigate the inﬂuence of IFN-γ on IDO1 expression
in the human colonic epithelial cell line CCD841 and compare the
ﬁndings with the mouse dendritic cell line DC2.4. We treated CCD841
cells with human IFN-γ (10 ng/mL) and DC2.4 cells with mouse IFN-γ
(20 ng/mL) for 24 h and then assessed the expression levels of IDO1
mRNA. Cells cultured in the absence of IFN-γ served as controls. We
found the expression of the enzyme to be induced markedly by IFN-γ
in both cell types: ~300-fold in CCD841 cells (Fig. 1A) and ~70-fold in
DC2.4 cells (Fig. 1B). These data show that IDO1 is induced by IFN-γ in
immune cells as well as in epithelial cells.
3.2. IFN-γ-induced IDO1 expression is associated with a concomitant
induction of a tryptophan-selective transporter in colonic epithelial cells
and immune cells
Since IDO1-mediated tryptophan catabolism is obligatorily
dependent on the availability of tryptophan within the cells, we askedwhether IFN-γ that induces IDO1 also facilitates the entry of tryptophan
into cells to optimize the substrate availability to the enzyme. A Na+-
independent, tryptophan-selective uptake system has been shown to
be present in IDO1-expressing cells [16,17], but the inﬂuence of IFN-γ
on this transport system has never been investigated. To address this
issue, we studied tryptophan uptake in control and IFN-γ-treated
CCD841 cells and DC2.4 cells. Initially we compared tryptophan uptake
in these cells in the presence and absence of Na+ and found that the
Table 2
Mouse primer sequences used for real-time quantitative RT-PCR.
Protein name Gene name Orientation Sequence
ASCT1 SLC1A4 Forward TGC TCT GGC GTT CAT CAT CA
ASCT1 SLC1A4 Reverse AGT GAA TGC GGC AAC CAC AA
ASCT2, AAAT SLC1A5 Forward TGG CCA GCA AGA TTG TGG AGA T
ASCT2, AAAT SLC1A5 Reverse TTT GCG GGT GAA GAG GAA GT
rBAT SLC3A1 Forward ATG TCA ACG CCA TGC ACA TGC T
rBAT SLC3A1 Reverse AGG TGT GGT TGG CCT CAG TAA A
4F2hc SLC3A2 Forward ACC TAC TGA ACA CTC CAC CG
4F2hc SLC3A2 Reverse TCA TGT CCA CTT CGG TGT CC
ATB0,+ SLC6A14 Forward CGG CCA GGA CAA CTT CCC AGT
ATB0,+ SLC6A14 Reverse GCC ACT AGG CCA CCC CAA GC
B0AT1 SLC6A19 Forward TTC ACA TCT GTG TAT GCG GCC A
B0AT1 SLC6A19 Reverse AGT GGC ATT GCA CCA CTG TT
CAT-1 SLC7A1 Forward ATG CCA TGG CTG AAG ATG GAC T
CAT-1 SLC7A1 Reverse AAA CAC AGG CAG CCA CCA AA
CAT-2 SLC7A2 Forward ACT TCT TTG CCG TGT GCC TTG T
CAT-2 SLC7A2 Reverse TTT CAC AAA CCC AGC CAC CA
LAT1 SLC7A5 Forward ATG GAG TGT GGC ATT GGC TT
LAT1 SLC7A5 Reverse TGC ATC AAC TTC TGG CAG AGC A
LAT2 SLC7A8 Forward AGC GAA ACA ACA CCG CGA AGA A
LAT2 SLC7A8 Reverse TTT CCA GCA CAC CTT TCG GT
b0,+ SLC7A9 Forward TGC AGA GCT TGG CAC AAT GA
b0,+ SLC7A9 Reverse AGG AGG CTT GCA ACC TGA GTA A
xCT SLC7A11 Forward TGC AAT CTG CAT CTC CAT GGC T
xCT SLC7A11 Reverse AAG CAG GAG AGG GCA ACA AA
MCT5 SLC16A4 Forward GGT GGC TAC CTG GCA CTA AT
MCT5 SLC16A4 Reverse ATC CAG CCT GCT ATT GGT GGT
MCT6 SLC16A5 Forward GGC ATG GTA GTC AGC ACC TT
MCT6 SLC16A5 Reverse ACA AGC CCA CTA CCG TGA TG
MCT7 SLC16A6 Forward CCT CCT TCT CCC AAA GGG TC
MCT7 SLC16A6 Reverse GCT GTG ATA GCT GGT GCG AA
MCT9 SLC16A9 Forward GAG CAG TCT TGC CCC CAA TA
MCT9 SLC16A9 Reverse ACC CAC ACT CGA ACC TGT TG
TAT1, MCT10 SLC16A10 Forward GTG CCT TAC GTT CAC TTG ATG A
TAT1, MCT10 SLC16A10 Reverse TGG ACA TCA GGC CAA TGA AGA A
MCT11 SLC16A11 Forward CGG AGC ACT TTG AAC GAA GC
MCT11 SLC16A11 Reverse AAG CCA AGC GAG GTT AGG AC
MCT12 SLC16A12 Forward GGC AGT CAC CAG ATG TAT CTC CA
MCT12 SLC16A12 Reverse ATG ATC CCC GCT TGA CAG GA
MCT13 SLC16A13 Forward CTT CCT GAA CTG GTG GGG AC
MCT13 SLC16A13 Reverse ATC CCG GAG GTA GCC TGA TA
MCT14 SLC16A14 Forward GAT CGT GGG ACC TTT CAT CG
MCT14 SLC16A14 Reverse CAC TGC AGG TAG GTA AGC CA
PAT4 SLC36A4 Forward GGA TTT CGT TCC TGC AGA CCT
PAT4 SLC36A4 Reverse TGT GCA TAC AGT GGA CGG AA
SNAT1, ATA1 SLC38A1 Forward ACG CGT GCA CAC CAA AGT AT
SNAT1, ATA1 SLC38A1 Reverse AAA GAT GGC CGT CAG GAA GT
SNAT2, ATA2 SLC38A2 Forward TTG CAG GCC ACG CTA TTT CA
SNAT2, ATA2 SLC38A2 Reverse AGC ACA GCC AAT CGG ACA ACA A
SNAT3, SN1 SLC38A3 Forward TGG CCT GCT TAC GTG CAT CAA T
SNAT3, SN1 SLC38A3 Reverse AGC GAA ACA AAG GGC CAG GAT T
EEG1 SLC43A3 Forward GCC CGC CTG ATA GCC ATA TT
EEG1 SLC43A3 Reverse CCC AAA GAG GTT CCC AAT CTG T
CD147 EMMPRIN Forward GCC TGC GCG GCG GCT GGT TT
CD147 EMMPRIN Reverse CAC GGT CCA GCC GGG CAC CA
ACE2 Forward CAG CTG AGG CCG TTG TAT GA
ACE2 Reverse GGC TTG ATC TCT GCG AAG GT
IDO1 Forward TGG CAA ACT GGA AGA AAA AG
IDO1 Reverse AAT GCT TTC AGG TCT TGA CG
IDO2 Forward TGG CGG TTC TCG ATT AAG TG
IDO2 Reverse GGC TTT CTC CTT CCA AAT CC
HPRT Forward GCG TCG TGA TTA GCG ATG ATG AAC
HPRT Reverse CCT CCC ATC TCC TTC ATG ACA TCT
Fig. 1. IFN-γ treatment induces IDO1 in human CCD841 colonic epithelial cell line and
mouse DC2.4 dendritic cell line. (A) Real-time PCR showing the relative IDO1 mRNA
expression in IFN-γ-treated (10 ng/mL of human IFN-γ; 24 h) CCD841 cells versus
untreated CCD841 cells. ***, P b 0.001. (B) Real-time PCR showing the relative IDO1
mRNAexpression in IFN-γ-treated (20 ng/mL ofmouse IFN-γ; 24h)DC2.4 cells versus un-
treated DC2.4 cells. ***, P b 0.001.
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indicating that the transport system responsible for tryptophan entry
in these cells is Na+-independent with no or little involvement of any
Na+-dependent system. We then assessed the contribution of the
Na+-independent but polyspeciﬁc amino acid transporter LAT1
(SLC7A5), a leucine-preferring transporter, to tryptophan uptake in
these cells. Most cells express LAT1 and this transporter can mediate
the uptake of several amino acids including tryptophan with high
afﬁnity [21,22]. The Michaelis constant for the transport of leucine viaLAT1 is ~10 μM; therefore, we used 5mM leucine in the uptakemedium
to eliminate any tryptophan uptake that might occur via LAT1. The
presence of leucine did inhibit tryptophan uptake by about 50%,
indicating that LAT1 does contribute to tryptophan uptake in these
cells to a signiﬁcant extent. However, the remaining 50% of tryptophan
uptake activity did not occur via LAT1. It is the presence of a signiﬁcant
tryptophan uptake activity that is insensitive to leucine and not
mediated by LAT1 that is relevant to the present study because of the
focus on the tryptophan-selective transport activity rather than on the
polyspeciﬁc LAT1. Based on these initial experiments, subsequent
uptakemeasurementsweremade in the absence of Na+ but in the pres-
ence of 5 mM leucine to monitor the leucine-insensitive tryptophan
uptake system. We compared tryptophan uptake in control and IFN-γ-
treated CCD841 cells and DC2.4 cells under these uptake conditions.
We found a signiﬁcant increase in tryptophan uptake in both cell
types in response to IFN-γ treatment (Fig. 2A for CCD841 cells and
Fig. 2B for DC2.4 cells). We also analyzed the inﬂuence of IFN-γ on the
leucine-sensitive tryptophan uptake (i.e., LAT1-mediated uptake) and
found that IFN-γ treatment had no effect on the activity of this transport
system (data not shown).
We then sought to determine the substrate speciﬁcity of the induced
transporter. To address this, we conducted [3H]-tryptophan uptake in
IFN-γ-treated CCD841 and DC2.4 cells in the presence of a panel of
unlabeled amino acids (alanine, glycine, cysteine, serine, threonine,
tryptophan, phenylalanine, tyrosine, leucine, valine, isoleucine, methio-
nine, lysine and arginine). The concentration of [3H]-tryptophan was
0.1 μM and that of unlabeled amino acids was 1 mM. Under these con-
ditions, none of the amino acids tested except tryptophan competed
with [3H]-tryptophan for uptake. This is evident in CCD841 cells
(Fig. 2C) aswell as in DC2.4 cells (Fig. 2D). In contrast, unlabeled trypto-
phan abolished the uptake of [3H]-tryptophan almost entirely. We then
used a much lower concentration of unlabeled tryptophan (50 μM
instead of 1 mM) and found the uptake of [3H]-tryptophan to be
inhibited markedly even at this low concentration (data not shown),
indicating the high-afﬁnity nature of the transport system. These ﬁnd-
ings lead to the conclusion that IFN-γ induces a tryptophan-selective
transport system in the colonic epithelial cell line CCD841 as well as in
the mouse dendritic cell line DC2.4.3.3. Kinetic features of the IFN-γ-inducible tryptophan transport system
We then determined the kinetic parameters (Michaelis constant Kt
and maximal velocity Vmax) of the tryptophan-selective transport
Fig. 2. IDO1 expression is associatedwith induction of a tryptophan-selective transporter. [3H]-tryptophan (0.1 μM) uptake in CCD841 (A) andDC2.4 (B) cells cultured for 24 h in the pres-
ence and absence of 10 and 20 ng/mL of human andmouse IFN-γ, respectively. The transport functionwasmonitored bymeasuring tryptophan uptake for 2min inNMDG-chloride buffer
in the presence of 5 mM leucine. Control uptake measured in CCD841 and DC2.4 cells without IFN-γ treatment was taken as 100%. ***, P b 0.001; **, P b 0.01. Amino acid selectivity of the
IFN-γ-induced tryptophanuptake system inCCD841 (C) andDC2.4 (D) cells. Cellswere cultured in thepresence of 10 and20ng/mL of humanandmouse IFN-γ, respectively, for 24 h. [3H]-
tryptophan (0.1 μM) uptake wasmeasured in NMDG-chloride for 2min in the presence of 5mM leucine.When present, the concentration of unlabeled tryptophan and other amino acids
was 1 mM. Uptake values measured in the absence of competing amino acids were taken as 100%. ***, P b 0.001.
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monitored in the absence of Na+ but in the presence of 5 mM leucine.
The transport system was saturable in both cell types (Fig. 3A for
CCD841 cells; Fig. 3B for DC2.4 cells), and the uptake data ﬁt well to
a model describing a single saturable transport system. The values for
Kt and Vmax for CCD841 cells were 36 ± 6 μM and 62 ± 8 pmoles/
106 cells/2 min; the corresponding values for DC2.4 cells were 0.5 ±
0.1 μM and 1.3 ±− .3 pmoles/106 cells/2 min. These ﬁndings lead to
the conclusion that the IFN-γ-inducible tryptophan-selective transport
system is of a high-afﬁnity type in both cell types. Interestingly, the
data show a signiﬁcant species-speciﬁc difference in the afﬁnity; the
afﬁnity of the transport system for tryptophan is almost 70-fold higher
in the mouse cell line DC2.4 compared to that in the human cell line
CCD841.3.4. Tryptophan selectivity of the IFN-γ-inducible transport system in the
presence of physiological concentrations of amino acids
We then wanted to conﬁrm the induction of the tryptophan-
selective transport system by IFN-γ in both cell types even when
assessed in the presence of physiological concentrations of all amino
acids. This was done by measuring [3H]-tryptophan uptake in IFN-γ-
treated CCD841 cells and DC2.4 cells in the presence of an amino acid
mixture consisting of 18 different amino acids, each at its respective
physiological concentrations found in plasma [18]. Again, cells cultured
in the absence of IFN-γ were used as controls. IFN-γ-mediated
induction of tryptophan uptake was noticeable even under theseexperimental conditions mimicking a physiological situation (Fig. 4A
for CCD841 cells; Fig. 4B for DC2.4 cells).
3.5. Evidence for the non-involvement of the Na+-independent amino acid
transporter PAT4 in IFN-γ-inducible tryptophan uptake
Until recently, among the multitude of amino acid transporters that
have been characterized at the molecular level, LAT1 (SLC7A5) was
the only transporter that was capable of tryptophan uptake with high
afﬁnity. Therefore, previously published reports [16,17] as well as the
present study had to address the issue of whether or not the IFN-γ-
inducible tryptophan uptake in IDO1-expressing cells occurs via LAT1.
These studies concluded that the IFN-γ-inducible tryptophan uptake
system is not identical to LAT1 at the molecular level. A more recent
study has identiﬁed another amino acid transporter, PAT4 (SLC36A4),
as capable of transporting tryptophanwith high afﬁnity (Michaelis con-
stant, ~2 μM) [23]. This transporter belongs to the family of proton-
coupled amino acid transporters with high afﬁnity for proline [24].
Therefore, we sought to determine the relevance of PAT4 to the IFN-γ-
inducible tryptophan uptake. PAT4 is Na+-dependent and has high
afﬁnity for tryptophan; but it also has high afﬁnity for proline. As such,
the relevance of PAT4 to the present investigation could be assessed
easily by studying the effect of proline on tryptophan uptake. We used
IFN-γ-treated DC2.4 cells for this purpose and compared the efﬁcacy
of proline and unlabeled tryptophan to compete with [3H]-tryptophan
(0.1 μM) for uptake (Fig. 4C). Proline did not inhibit [3H]-tryptophan
uptake even at a concentration as high as 1 mM whereas unlabeled
tryptophan, as expected, showed robust competition with radiolabeled
Fig. 3. Substrate saturation kinetics of the IFN-γ-induced tryptophan-selective transport
system in CCD841 cells (A) and in DC2.4 cells (B). Cells were treated with human and
mouse IFN-γ, respectively, for 24 h. Tryptophan uptake was measured at increasing
concentrations of tryptophan (0.3–100 μM) in CCD841 cells and (0.2–10 μM) in DC2.4
cells. [3H]-tryptophan (0.1 μM) was present as the tracer during uptake measurements.
The uptake buffer contained NMDG-chloride (in place of NaCl) and 5 mM leucine. Values
are the means ± S.E.M. (n = 6). Inset, Eadie–Hofstee plot (V versus V/S; V, tryptophan
uptake in pmol/106 cells per 2 min; S, tryptophan concentration in μM).
Fig. 4. Tryptophan uptake in the presence of physiological concentrations of amino acids
reconﬁrms the speciﬁcity of the tryptophan transporter. [3H]-tryptophan (0.1 μM) uptake
in CCD841 cells (A) and DC2.4 cells (B) cultured for 24 h in the presence of human and
mouse IFN-γ, respectively. Uptake was conducted in NMDG-chloride buffer containing
18 different amino acids (but no tryptophan), all at their normal physiological concentra-
tions in plasma [18]. ***, P b 0.001. (C) Dose–response relationship for the inhibition
of [3H]-tryptophan (0.1 μM) uptake by proline and unlabeled tryptophan in DC2.4 cells
treated with mouse IFN-γ (20 ng/mL; 24 h). The concentrations of the inhibitors ranged
from 1 to 1000 μM. Values are the means ± S.E.M. (n = 6).
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(data not shown). These data rule out involvement of PAT4 in IFN-γ-
inducible tryptophan uptake in both cell types.
3.6. Efﬁcacy of L-1-methyl tryptophan versus D-1-methyl tryptophan for the
inhibition of IFN-γ-inducible tryptophan uptake
L-1-Methyl tryptophan (L-1-MT) is an inhibitor of IDO1whereas D-1-
methyl tryptophan (D-1-MT) is not [25–27]. Therefore, the L-isomer is
routinely used in vitro and in vivo to determine the consequences of
IDO1 inhibition. Here we examined the inﬂuence of L-1-MT on the
IFN-γ-induced tryptophan-selective transport system because the
ability of this molecule to interfere with IDO1-induced tryptophan
depletion may not be solely due to its inhibitory effect on IDO1 activity
but may also involve potential inhibition of tryptophan entry into
IDO1-expressing cells. For this, we investigated the inﬂuence of both
stereoisomers of 1-MT on the tryptophan-selective uptake system in
IFN-γ-treated CCD841 cells and DC2.4 cells. L-1-MT or D-1-MT was
present only in the uptake medium along with tryptophan to see if
these tryptophan derivatives interfere with tryptophan uptake in
IFN-γ-treated cells. We observed that the L-isomer was highly effective
in inhibiting tryptophan uptake in both cell types with an IC50 value of
54 ± 4 μM in CCD841 cells (Fig. 5A) and 5 ± 1 μM in DC2.4 cells
(Fig. 5B). In contrast, the D-isomer had almost no effect. These data
suggest that L-1-MT is not only an inhibitor of IDO1 activity but also
an inhibitor of tryptophan entry into IDO1-expressing cells. On
the other hand, the D-isomer shows no effect on the IFN-γ-inducible
tryptophan transporter.3.7. Induction of the tryptophan-selective transport system by aryl
hydrocarbon receptor
Kynurenine is a catalytic endproduct of IDO1 and it is a physiological
agonist for the aryl hydrocarbon receptor (AhR). Activation of AhR
induces IDO1 [28–31]. We therefore asked whether AhR signaling, just
like IFN-γ signaling, is also involved in coordinated induction of the
tryptophan-selective transport system along with the induction of
IDO1. To address this question, we examined the effects of kynurenine
treatment on the activity of the tryptophan-selective transport system
in CCD841 cells. Cells cultured under identical conditions but in the
absence of kynureninewere used as controls.We found that kynurenine
treatment increased the activity of the tryptophan-selective transporter
to a signiﬁcant extent (Fig. 6A).We then examined the effects of several
pharmacological agonists of AhR in the same cell line. With each of
the agonist examined, we found a signiﬁcant increase in the activity of
the tryptophan-selective transport system compared to cells cultured
in the absence of the agonists (Fig. 6B). These ﬁndings lead to the
conclusion that AhR signaling induces not only IDO1 expression as
evident from published reports but also the tryptophan entry into
IDO1-expressing cells.3.8. Attempts to identify the IFN-γ-inducible tryptophan-selective transporter
To establish the molecular identity of the tryptophan-selective
transporter that is induced by IFN-γ in IDO1-expressing cells, we took
Fig. 5. Interaction of the IDO1 inhibitor 1-methyl tryptophan (1MT) with the tryptophan-
selective transporter. Dose–response relationship for inhibition of tryptophan (0.1 μM)
uptake (NMDG-chloride buffer; 5 mM leucine) by D-1-MT and L-1-MT examined in IFN-
γ-treated CCD841 (A) and DC2.4 (B) cells. The concentrations of the inhibitors ranged
from 1 to 1000 μM. Values are the means ± S.E.M. (n = 6).
Table 3
Real-time quantitative RT-PCR with CCD841 cells.
Sr. No. Protein name Gene name +IFN-γ treated SE
Control 1.00 0.03
1 ASCT1 SLC1A4 0.76 0.08
2 ASCT2 SLC1A5 1.07 0.02
3 rBAT SLC3A1 1.06 0.25
4 4F2hc SLC3A2 0.75 0.04
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transporters that included those that have already been established as
amino acid transporters, others that currently remain as orphan trans-
porters with no known transportable substrates, and transporter chap-
erones that do not function by themselves as transporters but facilitate
the stability and plasma membrane recruitment of certain amino acid
transporters. We compared the expression levels of these ~30 genes
by qPCR between control and IFN-γ-treated CCD841 cells and DC2.4
cells. The rationale for this approach was that IFN-γ treatment induces
a tryptophan-selective transport system in these cells and thereforeFig. 6. Activation of aryl hydrocarbon receptor (AhR) induces the tryptophan-selective
transporter. (A) [3H]-tryptophan (0.1 μM) uptake measured for 2 min in CCD841 cells
(NMDG-chloride buffer; 5 mM leucine) that had been cultured in the presence and
absence of 1 mM kynurenine for 24 h. ***, P b 0.001. (B) [3H]-tryptophan (0.1 μM) uptake
measured for 2 min in CCD841 cells (NMDG-chloride; 5 mM leucine) that had been
cultured in the presence of various AhR ligands for 24 h: TCDD (10 nM), BaP (5 μM),
3MCA (5 μM) and I3C (50 μM). *, P b 0.05; **, P b 0.01; ***, P b 0.001.must be associated with an increase in the steady-state levels of the
mRNA for the transporter in both cell types. Comparison of the mRNA
levels for the potential transporter genes between control and IFN-γ-
treated cells might lead to identiﬁcation of the transporter. The second
was a non-biased approach that involved analysis of transcriptome by
microarray in control and IFN-γ-treated CCD841 cells with the goal to
identify the transporter genes that are induced by IFN-γ as the potential
candidates for the tryptophan-selective transporter.
The real-time PCR data for CCD841 cells and DC2.4 cells are given in
Tables 3 and 4, respectively. In CCD841 cells, we identiﬁed six trans-
porters that were induced signiﬁcantly by IFN-γ; these are SLC6A14
(ATB0,+), SLC6A19 (B0AT1), SLC7A2 (CAT2), SLC7A8 (LAT2), SLC7A9
(b0,+) and SLC16A11 (MCT11). The same six transporters were also
induced in DC2.4 cells. Among these transporters, ﬁve of them have
already been characterized at the functional level, and the functional
features of these ﬁve transporters did not match those of the IFN-γ-
induced tryptophan-selective transporter, thus ruling them out as the
potential candidates for the transport system. SLC16A11 seemed a
promising candidate because it has no known transport function and
it is induced by IFN-γ in both cell types. Therefore, we cloned this trans-
porter, functionally expressed in mammalian cells, and examined its
ability to transport tryptophan. These studies failed to show tryptophan
uptake activity for the transporter (data not shown). There were four
additional transporter genes that were induced by IFN-γ in DC2.4 cells
(SLC7A11, SLC16A5, SLC16A9, and SLC43A3), but these genes were
not induced in CCD841 cells. Since IFN-γ induced the tryptophan-
selective transport activity in both cell types, induction in one cell type
but not in the other made it very unlikely that any of these four trans-
porters represents the tryptophan-selective transporter.
We then examined the transcriptome proﬁles in control and IFN-γ-
treated CCD841 cells for the genes belonging to the known SLC gene
families. The microarray data contained expression information for a
total of 430 transporter genes, of which ~90% of the genes remained
largely unaffected by IFN-γ treatment. Among the genes that were
upregulated at least by 50% were SLC2A3 (glucose transporter 3),
SLC6A6 (taurine transporter), SLC6A12 (betaine transporter), SLC9A75 ATB0,+ SLC6A14 4.08 0.26
6 B0AT1 SLC6A19 2.01 0.22
7 CAT-1 SLC7A1 0.91 0.01
8 CAT2 SLC7A2 1.86 0.13
9 LAT1 SLC7A5 0.82 0.03
10 LAT2 SLC7A8 6.46 1.04
11 b0,+ SLC7A9 2.46 0.51
12 xCT SLC7A11 0.85 0.13
13 MCT5 SLC16A4 1.03 0.08
14 MCT6 SLC16A5 1.07 0.02
15 MCT7 SLC16A6 0.96 0.06
16 MCT9 SLC16A9 1.00 0.31
17 TAT1, MCT10 SLC16A10 0.67 0.02
18 MCT11 SLC16A11 3.19 0.30
19 MCT12 SLC16A12 1.67 0.15
20 MCT13 SLC16A13 0.72 0.03
21 MCT14 SLC16A14 0.50 0.03
22 PAT4 SLC36A4 0.98 0.03
23 SNAT1, ATA1 SLC38A1 0.83 0.01
24 SNAT2, ATA2 SLC38A2 0.95 0.02
25 SNAT3, SN1 SLC38A3 0.95 0.04
26 EEG1 SLC43A3 0.95 0.02
27 CD147 EMMPRIN 1.09 0.16
28 ACE2 0.91 0.31
29 IDO1 21466.20 1249.55
Table 4
Real-time quantitative RT-PCR in DC2.4 cells.
Sr. No. Protein name Gene name +IFN-γ treated SE
Control 1.00 0.03
1 ASCT1 SLC1A4 0.59 0.02
2 ASCT2 SLC1A5 0.83 0.01
3 rBAT SLC3A1 0.35 0.04
4 4F2hc SLC3A2 0.71 0.07
5 ATB0,+ SLC6A14 2.62 0.12
6 B0AT1 SLC6A19 34.21 13.02
7 CAT-1 SLC7A1 0.93 0.02
8 CAT-2 SLC7A2 3.78 0.17
9 LAT1 SLC7A5 0.85 0.03
10 LAT2 SLC7A8 2.70 0.09
11 b0,+ SLC7A9 455.16 102.02
12 xCT SLC7A11 1.90 0.04
13 MCT5 SLC16A4 1.83 0.19
14 MCT6 SLC16A5 1.22 0.24
15 MCT7 SLC16A6 1.31 0.02
16 MCT9 SLC16A9 1.83 0.32
17 TAT1, MCT10 SLC16A10 0.96 0.04
18 MCT11 SLC16A11 7.03 0.60
19 MCT12 SLC16A12 0.60 0.04
20 MCT13 SLC16A13 0.90 0.04
21 MCT14 SLC16A14 0.19 0.01
22 PAT4 SLC36A4 0.84 0.01
23 SNAT1, ATA1 SLC38A1 0.72 0.00
24 SNAT2, ATA2 SLC38A2 0.63 0.02
25 SNAT3, SN1 SLC38A3 2.16 1.02
26 EEG1 SLC43A3 4.46 0.18
27 CD147 EMMPRIN 1.66 0.13
28 ACE2 1.46 0.38
29 IDO1 73.20 2.18
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mitochondrial glutamate transporter), SLC22A28 (a member of the
anion/cation transporter gene family), SLC37A1 (glucose-6-phosphate
transporter), and SLC37A3 (a lysosomal sugar phosphate exchanger)
(Supplemental Table 1). The functional identities of all of these
transporters are already known, and it is unlikely that any of them has
the ability to transport tryptophan, thus ruling them out as potential
candidate genes for the tryptophan-selective transporter. Among the
transporter genes thatwere downregulated, only 6 genes showedquan-
titatively signiﬁcant reduction in expression (N30%) (Supplemental
Table 2). These genes are not likely to do anything with the tryptophan-
selective transporter because of the suppressing effect instead of the
inductive effect of IFN-γ on their expression.
4. Discussion
Herewe report for theﬁrst time that IFN-γ, which is known to induce
the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase-1
(IDO1), also induces a tryptophan-selective transporter in colonic
epithelial cells and in dendritic cells. This is a very important ﬁnding
because the primary purpose for the induction of IDO1 is to promote
intracellular degradation of tryptophan with consequent depletion of
this essential amino acid in the extracellular milieu. It is this decreased
availability of tryptophan in the extracellular medium that suppresses
T cell proliferation and causes immune tolerance. This whole rationale
however relies on effective transfer of tryptophan from the extracellular
medium into IDO1-expressing cells. Therefore, a concomitant induction
of a tryptophan transport system along with IDO1 is necessary for this
process to occur in an effective manner. Our data showing that IFN-γ
coordinately induces IDO1 as well as a tryptophan-selective transporter
provide a molecular basis for the ability of the enzyme to deplete this
essential amino acid in the extracellular medium. The existence of a
tryptophan-selective transporter in IDO1-expressing cells has been
demonstrated previously in two different laboratories [16,17] but this
is the ﬁrst time that the inﬂuence of IFN-γ on the transporter is reported.The selectivity of the transporter to tryptophan is unique among the
known amino acid transport systems, but since the function of the
transporter is coupled to IDO1, an enzyme that degrades tryptophan,
biologically this selectivity does make sense. Another interesting aspect
of the present study is the demonstration that L-1-methyl tryptophan
(L-1-MT) interferes with the transfer of tryptophan into cells via the
transporter. This tryptophan derivative is widely used to inhibit the
activity of IDO1 and it does prevent the enzyme-induced tryptophan
depletion and its consequences [25–27]. But until now it has been
assumed that IDO1 is the sole target for this compound. Our studies
show that L-1-MT not only inhibits IDO1 but also blocks tryptophan
entry into cells. The D-isomer (D-1-MT) exhibits a much lower efﬁcacy
in blocking tryptophan transport via the transporter. It is interesting to
note that this isomer does not inhibit IDO1 also. Even though it is the
L-isomer that is capable of preventing IDO1-induced tryptophan deple-
tion, the D-isomer has been found to be effective in vivo in blocking the
IDO1-dependent immunotolerance in some mouse models [5]. The
molecular basis of the efﬁcacy of the D-isomer in vivo is not well under-
stood. It is possible that the D-isomer has a much greater half-life than
the L-isomer due to the lack of robust enzyme activities to metabolize
the D-isomer; therefore, even though D-1-MT is less effective than L-1-
MT in inhibiting IDO1 and the tryptophan transporter, the pharmacoki-
netics of D-1-MT may be more favorable than L-1-MT in vivo to prevent
IDO1-induced tryptophan depletion. Alternatively, the ability of the
D-isomer to block the IDO1-induced immunotolerance may not have
anything to do with IDO1 and tryptophan entry; the compound might
have some other, not yet identiﬁed, biological targets in cells.
The third observation in the present study that has functional
and biological signiﬁcance to IDO1-induced tryptophan depletion
and immunotolerance is the ability of kynurenine to induce the
tryptophan-selective transporter via the aryl hydrocarbon receptor
(AhR). It is already known that AhR is capable of inducing IDO1
[28–31], but the present study demonstrates that AhR is also capable
of inducing the transporter responsible for the entry of tryptophan in
IDO1-expressing cells. The coordinated induction of IDO1 and the tryp-
tophan transporter by kynurenine suggests the existence of a positive
feedback loop in the process. When tryptophan is degraded by IDO1,
it generates kynurenine, which then induces the expression of the
tryptophan transporter and IDO1 by serving as an agonist for AhR,
thus amplifying the signal to elicit further depletion of tryptophan. A
previous study has shown that exogenous expression of IDO1 in mam-
malian cells leads to induction of the tryptophan-selective transporter
[7], but the molecular mechanism underlying the phenomenon has
not been determined. Our ﬁndings that kynurenine induces the trans-
porter via AhR indicate that the IDO1-dependent induction of the trans-
porter occurs most likely via the kynurenine-AhR signaling pathway.
Though it is unequivocal from the present study as well as from
the other two previous studies that IDO1-expressing cells have a func-
tionally active tryptophan-selective transporter, the molecular identity
of the transporter remains unknown. The transport activity does not
seem to represent or resemble the function of any of the already charac-
terized amino acid transporters. The present studies represent the ﬁrst
comprehensive attempt to identify the transporter at the molecular
level. Unfortunately, these studies also failed to establish the molecular
identity of the transporter. Since the list of the transporter genes thatwe
examined in the present study for tryptophan-selective transport
function included several orphan transporters, it is possible that the
transporter represents the product of a novel transporter gene not yet
identiﬁed. It is also possible that, like many of the known amino acid
transporters, the tryptophan-selective transporter requires a chaperone
for its function and that the induction of this chaperone is responsible
for the IFN-γ-inducible tryptophan uptake activity. The list of genes
that we examined in the present studies did include all of the known
chaperones associated with amino acid transporters, but it is possible
that the chaperone associatedwith the tryptophan-selective transporter
is different from the ones that have been already identiﬁed. Thus, the
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remains elusive.
Despite the failure of the present study to successfully establish the
molecular identity of the tryptophan-selective transporter in IDO1-
expressing cells, there is no doubt about the biological and therapeutic
importance of the transporter. Without the function of the transporter,
IDO1 will not be effective in depleting tryptophan in the extracellular
environment to elicit T cell anergy. The transporter and the enzyme
have to be functionally coupled for this purpose. The coordinated
induction of both genes by IFN-γ underscores the obligatory nature of
this functional coupling. The positive feedback loop in the control of
the expression of the transporter and the enzyme through kynurenine-
AhR signaling also highlights the signiﬁcance of the functional coopera-
tion between the two proteins. The therapeutic relevance of the
transporter is readily apparent. Currently, only IDO1 is being investigated
as a drug target for the modulation of immune function via tryptophan
catabolism. The fact that IDO1 cannot bring about tryptophan catabolism
without partnering with the tryptophan transporter indicates that the
transporter is also a potential drug target to modulate immune function.
Ideally, an inhibitor that blocks the function of the transporter as well as
that of the enzyme would be desirable for this purpose because such an
inhibitor would be more effective in preventing tryptophan catabolism
than the inhibitors that target either the transporter or the enzyme
individually.
There is a growing interest in the potential use of IDO1 inhibitors as
anticancer drugs [13–15]. The enzyme is induced in immune cells
present in tumor-draining lymph nodes where it is thought to play a
role in suppressing T cell proliferation and consequently promote the
escape of tumor cells from attack by cytotoxic T cells. Based on this
proposed mechanism, pharmacological inhibition of IDO1-mediated
tryptophan catabolism is expected to enhance immune surveillance
and suppress tumor growth via T cell-mediated antitumor immunity.
Several studies with preclinical animal models of breast cancer, ovarian
cancer and melanoma have provided evidence in support of antitumor
activity of IDO1 inhibitors, effective either alone or in combination
with chemotherapy [32–35]. There are reasons to believe that the bio-
logical function of IDO1, tryptophan-selective amino acid transporter,
and tryptophan catabolism and their relevance to inﬂammation and
carcinogenesis might be different in colon versus other organs. IDO1 is
expressed in normal colon and in immune cells located in lamina
propria where the enzyme-mediated tryptophan depletion and conse-
quent immune tolerance might be essential to facilitate the existence
of normal microbiota in the host colon. In the present study we have
shown that IDO1 and the tryptophan-selective amino acid transporter
are expressed not only in immune cells but also in colonic epithelial
cells. It is likely that IDO1-mediated tryptophan depletion occurs in
both cell types in normal colon contributing to the maintenance of
immune tolerance. Pharmacological blockade of IDO1 and tryptophan-
selective amino acid transporter in colon would interfere with this
phenomenon and promote inﬂammation, particularly in view of the
fact that the colonic epithelial cells and immune cells are constantly
exposed to bacterial antigens. It is well known that inﬂammation is a
potent driver of colon carcinogenesis, suggesting that inhibition of
IDO1-mediated tryptophan depletion may actually promote colon
cancer. The ﬁndings from published reports on the consequences of
IDO1 loss or inhibition in colon are conﬂicting, some studies showing
suppression of colon cancer [36,37] while others showing enhancement
of colon cancer [38]. Further studies are needed in this area to evaluate
the role of IDO1-mediated tryptophan depletion in colonic epithelial
cells and immune cells under normal and pathological conditions.Acknowledgements
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